Matinas BioPharma (MTNB)
XASE:MTNB
Want to see MTNB full AI Analyst Report?
Top Page
Matinas BioPharma
(NYSE MKT:MTNB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.61
▼(-6.77% Downside)
Action:Reiterated
Date:06/27/26
Overall score is weighed down primarily by weak financial performance (no revenue, continued losses, and ongoing cash burn despite some improvement) and bearish technical signals (negative MACD, low RSI, and trading below key moving averages). Valuation contributes only modestly because the negative P/E is not informative in a loss-making context and no dividend support is provided.
Positive Factors
Narrowing losses
The material reduction in annual losses demonstrates improving cost control or program prioritization, which lengthens runway and reduces near-term fundraising pressure. Over 2–6 months this trend supports more sustainable R&D funding and increases the probability management can execute clinical milestones without immediate dilution.
Negative Factors
No revenue
Lack of any product revenue means the company remains entirely pre-commercial, with no validated sales or margins to absorb R&D costs. Structurally this increases reliance on external financing, raises dilution risk, and leaves profitability and scalable cash generation contingent on uncertain clinical and regulatory outcomes over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing losses
The material reduction in annual losses demonstrates improving cost control or program prioritization, which lengthens runway and reduces near-term fundraising pressure. Over 2–6 months this trend supports more sustainable R&D funding and increases the probability management can execute clinical milestones without immediate dilution.
Read all positive factors
Matinas BioPharma (MTNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.12M
Dividend YieldN/A
Average Volume (3M)52.28K
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS Growth49.11%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,406,191
10 Day Avg. Volume45,057
30 Day Avg. Volume52,280
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit244.01
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Matinas BioPharma Business Overview & Revenue Model
Company Description
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology ...
How the Company Makes Money
null...
Matinas BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.10M | 3.19M | 33.00K |
| Gross Profit | 11.00K | -456.00K | 0.00 | 1.10M | -13.49M | -14.55M |
| EBITDA | -9.72M | -9.89M | -19.19M | -22.00M | -20.64M | -23.00M |
| Net Income | -11.23M | -10.35M | -24.25M | -22.94M | -21.00M | -23.28M |
Balance Sheet | ||||||
| Total Assets | 5.87M | 7.21M | 12.64M | 25.10M | 78.87M | 61.33M |
| Cash, Cash Equivalents and Short-Term Investments | 2.45M | 4.00M | 7.28M | 13.76M | 28.81M | 49.62M |
| Total Debt | 1.19M | 1.35M | 2.89M | 3.56M | 4.12M | 4.70M |
| Total Liabilities | 2.85M | 2.38M | 5.05M | 5.86M | 42.23M | 8.83M |
| Stockholders Equity | 3.02M | 4.83M | 7.59M | 19.25M | 36.64M | 52.49M |
Cash Flow | ||||||
| Free Cash Flow | -6.61M | -7.01M | -15.88M | -15.50M | -20.05M | -15.48M |
| Operating Cash Flow | -6.61M | -7.01M | -15.88M | -15.28M | -19.16M | -15.22M |
| Investing Cash Flow | 335.00K | 335.00K | 9.21M | 13.24M | 4.88M | 16.77M |
| Financing Cash Flow | 1.74M | 3.39M | 9.17M | -7.00K | 79.00K | 6.96M |
Matinas BioPharma Technical Analysis
Negative
0.65
Price Trends
0.67
Negative
0.63
Positive
0.90
Negative
Market Momentum
-0.01
Positive
42.62
Neutral
16.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.67, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 16.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.
Matinas BioPharma Risk Analysis
Matinas BioPharma disclosed 56 risk factors in its most recent earnings report. Matinas BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Matinas BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.60M | -0.26 | -155.01% | ― | ― | 75.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.45M | -0.17 | -253.43% | ― | ― | 97.61% | |
45 Neutral | $4.12M | -0.32 | -157.24% | ― | ― | 49.11% | |
45 Neutral | $9.78M | -0.45 | -87.05% | ― | -90.40% | 34.76% | |
44 Neutral | $7.38M | -0.12 | -102.39% | ― | 356.16% | 62.82% |
* Healthcare Sector Average
MTNB
Matinas BioPharma
0.64
-0.28
-30.22%
NCNA
Nucana
1.55
-15.63
-90.98%
ADIL
Adial Pharmaceuticals
2.56
-5.82
-69.44%
SILO
Silo Pharma
6.05
-3.57
-37.13%
APRE
Aprea Therapeutics
0.79
-0.89
-52.84%
HCWB
HCW Biologics
1.03
-3.47
-77.11%
Matinas BioPharma Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Matinas BioPharma Granted NYSE American Compliance Extension
Negative
Jun 26, 2026
On June 24, 2026, Matinas BioPharma received a notice from NYSE American that it was not in compliance with listing standards requiring minimum stockholders’ equity of $4 million, after previously being notified in April 2026 of non-complian...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Matinas BioPharma Faces NYSE American Listing Compliance Notice
Negative
Apr 3, 2026
On April 2, 2026, Matinas BioPharma received a notice from NYSE American that it is out of compliance with the exchange’s stockholders’ equity listing standards after posting losses in each of the five years through December 31, 2025, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.